A New Perspective: Understanding Testosterone and Prostate Cancer

Ultimo aggiornamento: Maggio 11, 2026

• Facebook
• Instagram
• WordPress
• Telegramma
• WhatsApp
• LinkedIn
• Posta

For decades, the medical community operated under a singular, frightening assumption: that testosterone is “fuel for the fire” when it comes to prostate cancer (PCa). If you were a man with a history of prostate cancer, testosterone therapy was strictly off the table — viewed as a dangerous catalyst that would inevitably accelerate tumor growth. However, we are now entering a “New Era” where modern evidence has challenged these long-held myths, leading to a fundamental paradigm shift in how we view men’s health.

During my time working with Professor Mohit Khera at Baylor College of Medicine, I had the privilege of discussing his influential research on the Saturation Model. This framework has revolutionized our understanding of the relationship between androgens and the prostate, providing a scientific basis for why the old fears may have been misplaced.

The Old Guard: The Androgen Hypothesis

To understand where we are going, we must look at where we started. In the 1940s, researchers Huggins and Hodges observed that depriving men of androgens (through castration or estrogen) improved the condition of those with metastatic prostate cancer. Conversely, administering testosterone seemed to cause rapid progression.

From these observations, the Androgen Hypothesis was born: the belief that higher testosterone promotes the development of PCa and lower testosterone is protective. For generations, medical students were taught that giving testosterone to a man with PCa was like “pouring gasoline on a fire.” This created a culture of fear — even today, an international survey showed that the risk of prostate cancer remains the primary concern for physicians considering testosterone therapy.

The Paradigm Shift: The Saturation Model

The Saturation Model, championed by experts like Dr. Khera and Dr. Abraham Morgentaler, offers a more nuanced explanation of how the prostate actually interacts with hormones.

The core idea is simple: the prostate has a finite capacity to use testosterone. Think of it like a sponge. Once a sponge is completely soaked, adding more water doesn’t make it “wetter.” Similarly, the androgen receptors (AR) in the prostate become “saturated” at relatively low levels of serum testosterone.

Key Mechanics of Saturation

• Threshold Effect: Prostate tissue is exquisitely sensitive to changes in testosterone at very low concentrations (the “androgen-dependent” range).
• The Saturation Point: Once testosterone levels reach approximately 250 ng/dL (8 nmol/L), the receptors are fully bound.
• Androgen Indifference: Beyond this saturation point, the prostate becomes indifferent to further increases in testosterone. This explains why healthy men given massive, supraphysiologic doses of testosterone do not see an increase in their Prostate-Specific Antigen (PSA) levels or prostate volume.

This model reconciles the dual observations that while cancer is sensitive to testosterone at near-zero levels (which is why hormone deprivation therapy works), it does non continue to grow faster just because a man has high natural testosterone.

Challenging the Myths with Evidence

If the old hypothesis were true, men with high testosterone should have more cancer, and men with low testosterone should have less. However, the data tells the opposite story:

1. High Testosterone is Not a Risk: Over 20 longitudinal studies have shown no relationship between naturally high serum testosterone and the risk of developing prostate cancer.
2. Low Testosterone is Not Protective: Surprisingly, many studies suggest that low testosterone is actually associated with more aggressive, higher-grade tumors and a worse prognosis.
3. The PSA-to-Testosterone Ratio: Research suggests that a high ratio of PSA to testosterone can be a better predictor of cancer risk than PSA alone, especially in men with low testosterone levels.

Clinical Implications: A New Path Forward

The realization that testosterone does not “feed” the tumor once the saturation point is reached has opened the door for treating symptomatic men who were previously left in the dark. Men with hypogonadism (testosterone deficiency) suffer from fatigue, depression, bone density loss, and sexual dysfunction. For many of these men who have also survived prostate cancer, the lack of treatment was a significant blow to their quality of life.

Testosterone Therapy After Treatment

Multiple small-scale studies have now followed men who received testosterone therapy after undergoing a Radical Prostatectomy (RP) or radiation therapy:

• Post-Surgery: In one of the largest series to date, men who received testosterone therapy after surgery actually had a lower rate of biochemical recurrence (4%) compared to a control group (16%).
• Post-Radiation: Studies on men following brachytherapy and external-beam radiation have shown similarly reassuring results, with very low or absent recurrence rates.

The Most Bold Step: Active Surveillance

Perhaps the most provocative area of research involves men on Active Surveillance — those with known, untreated, low-grade prostate cancer. In a study led by Dr. Morgentaler and colleagues (including Dr. Khera), 13 men on active surveillance were treated with testosterone therapy for an average of 2.5 years. The results were stunning: there was no definite cancer progression in any of the men, and in 54% of the follow-up biopsies, no cancer was found at all.

Safety and Cautionary Guidelines

While the “New Era” is promising, the medical community remains appropriately cautious. We still lack large-scale, long-term randomized controlled trials to guarantee absolute safety. Therefore, Dr. Khera and his colleagues recommend strict criteria before starting therapy for anyone with a history of PCa:

Criterion	Requirement
Diagnosis	Clinical symptoms must match a diagnosis of testosterone deficiency.
Consent	The patient must understand that long-term safety data are limited.
PSA Stability	The patient should have an undetectable or stable PSA level.
Monitoring	Rigorous follow-up, especially in the first year, is mandatory.
Exclusions	Therapy is not recommended for men currently on Androgen Deprivation Therapy (ADT).

Conclusion: The Future of Men’s Health

The shift from the Androgen Hypothesis to the Saturation Model represents one of the most significant changes in urological history. It moves us away from a “one-size-fits-all” prohibition and toward personalized medicine, where we can treat the whole patient rather than just a laboratory value.

Working at Baylor with Dr. Khera, it became clear that our goal is not just to extend life, but to ensure that life is worth living. By understanding that testosterone’s effect on the prostate is limited by the saturation of its receptors, we can finally begin to offer relief to men who have long been told that their symptoms were a necessary price to pay for their cancer survival.

As we look toward the next 15 years, the possibility even exists that testosterone therapy might one day play a role in prophylaxis (prevention), as we continue to see that a healthy hormonal environment is often the best defense against aggressive disease.

If you are a prostate cancer survivor or have been told you cannot consider testosterone therapy due to PCa concerns, it may be worth seeking a second opinion based on the latest evidence. Dr. Soarawee Weerasopone offers specialist consultations in men’s health and testosterone therapy at Bangkok Hospital Headquarters. Prenota una consulenza.

Frequently Asked Questions About Testosterone and Prostate Cancer

Does testosterone therapy cause prostate cancer?

Current evidence does not support the long-held belief that testosterone causes prostate cancer. Over 20 longitudinal studies have found no link between naturally high testosterone levels and PCa risk. The Saturation Model, developed by Dr. Khera and Dr. Morgentaler, explains why: prostate androgen receptors become fully saturated at relatively low testosterone levels (around 250 ng/dL), so additional testosterone does not stimulate further growth.

Is it safe to take testosterone after prostate cancer surgery?

Multiple studies suggest yes, when proper criteria are met. In one of the largest series to date, men who received testosterone therapy after radical prostatectomy had a lower rate of biochemical recurrence (4%) compared to controls (16%). However, treatment requires undetectable or stable PSA, rigorous monitoring, and shared decision-making with a urologist.

What is the Saturation Model in simple terms?

Think of the prostate like a sponge. Once it is fully soaked with testosterone, adding more does not make it “wetter.” The prostate’s androgen receptors become saturated at relatively low testosterone levels, so beyond that point, the prostate becomes indifferent to additional testosterone. This is why men with very high natural testosterone do not have higher prostate cancer rates.

Is low testosterone protective against prostate cancer?

No — in fact, the opposite may be true. Several studies suggest that low testosterone is associated with more aggressive, higher-grade prostate tumors and a worse prognosis. The PSA-to-testosterone ratio may also be a more reliable risk indicator than PSA alone, especially in men with low testosterone levels.

Medically written & reviewed by: Dr. Soarawee Weerasopone (Dr. Pom) — Board-Certified Urologist, Bangkok Hospital Headquarters.
International Fellow: Baylor College of Medicine (USA) · Juntendo University (Japan) · Chang Gung Memorial Hospital (Taiwan).

Disclaimer: Questo contenuto è redatto e revisionato dal Dr. Soarawee Weerasopone, urologo certificato presso il Bangkok Hospital Headquarters. È inteso solo a scopo educativo e non costituisce consulenza medica. Consultare sempre un professionista sanitario qualificato prima di iniziare qualsiasi trattamento medico.